Initial FDA approval was based primarily on studies from Europe suggesting the use of
STAN technology was associated with both a reduction in the rate of neonatal acidemia, which is high acid in the blood that can lead to brain defects and a decrease in the rate of surgical delivery.
The study sought to see if
the STAN technology improved perinatal outcomes or decreased surgical deliveries over conventional labor / delivery fetal heart rate monitoring.
Not exact matches
«It's a new
technology that will require new costs,» lead investigator Dr. George Saade, professor and division chief in the UTMB department of obstetrics and gynecology, said of
STAN.